2-[2-(2-Hydroxyethoxy)ethoxy]ethanol;pentanedioic acid | 179761-35-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[2-(2-Hydroxyethoxy)ethoxy]ethanol;pentanedioic acid
• CAS: 179761-35-4
• 化学式: C11H22O8
• 分子量: 282.29
• InChiKey: SBUMCKKGDYMCGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.67
• 重原子数：
  19
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Universal controlled-release composition comprising chitosan
  申请人：JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd.

  公开号：EP1512394A1

  公开（公告）日：2005-03-09

  The present invention relates to a controlled-release pharmaceutical composition comprising at least one active agent and an inactive matrix, said matrix comprising chitosan and derivatives thereof, and further comprising a hydrophilic polysaccharide polymer selected from the group of carbohydrate gums, specifically xanthan gum, and to the preparation and use of said composition.

  本发明涉及一种控释药物组合物，该组合物包含至少一种活性剂和一种非活性基质，所述基质包括壳聚糖及其衍生物，还包括一种亲水性多糖聚合物，该聚合物选自碳水化合物胶类，特别是黄原胶，本发明还涉及所述组合物的制备和使用。
• Chitosan-silicon dioxide coprecipitate and use as excipient in solid dosage forms
  申请人：The Jordanian Pharmaceutical Manufacturing Co.

  公开号：EP1759711A1

  公开（公告）日：2007-03-07

  Chitosan silicone dioxide coprecipitate composition, method of production thereof, pharmaceutical composition comprising the chitosan silicone dioxide coprecipitate composition and use of the chitosan silicone dioxide coprecipitate composition for manufacturing a sustained or immediate release formulation.

  壳聚糖二氧化硅共沉淀物组合物、其生产方法、包含壳聚糖二氧化硅共沉淀物组合物的药物组合物，以及壳聚糖二氧化硅共沉淀物组合物在制造缓释或即释制剂中的用途。
• Co-precipitate of chitin or chitin derivative and a silicon dioxide or derivative for the use as tablet excipient
  申请人：The Jordanian Pharmaceutical Manufacturing Co. Ltd.

  公开号：EP1852110A1

  公开（公告）日：2007-11-07

  The invention is related to a co-precipitate comprising at least one hydrophilic polymeric compound selected from the group consisting of chitin, chitin derivatives, other polyglucosamines, or any salts, solvates or mixtures thereof, and at least one water-absorbant compound selected from the group consisting of silicon dioxide, derivatives thereof, or any mixtures thereof, a method of preparing the same and novel uses thereof.

  本发明涉及一种共沉淀物，包含至少一种亲水性高分子化合物（选自甲壳素、甲壳素衍生物、其他聚葡糖胺或其任何盐类、溶剂或混合物组成的组别）和至少一种吸水性化合物（选自二氧化硅、其衍生物或其任何混合物组成的组别），以及制备方法和新用途。
• Drug delivery system for poorly water soluble drugs
  申请人：——

  公开号：US20030157171A1

  公开（公告）日：2003-08-21

  The present invention relates to a method for modifying the solubilization rates of poorly water soluble drugs, using a chitosan-xanthan hydrogel. In addition, the present invention relates to a process for the preparation of chitosan-xanthane hydrogels as well as for the preparation of hydrogels comprising a poorly water soluble drug.

  本发明涉及一种利用壳聚糖-黄原胶水凝胶改变水溶性差药物溶解速率的方法。此外，本发明还涉及一种壳聚糖-黄原酸酯水凝胶的制备方法以及包含水溶性差的药物的水凝胶的制备方法。
• Universal controlled-release composition
  申请人：Badwan Ali Adnan

  公开号：US20050281873A1

  公开（公告）日：2005-12-22

  The present invention relates to a controlled-release pharmaceutical composition comprising at least one active agent and an inactive matrix, said matrix comprising chitosan and derivatives thereof, and further comprising a hydrophilic polysaccharide polymer selected from the group of carbohydrate gums, specifically xanthan gum, and to the preparation and use of said composition.

  本发明涉及一种控释药物组合物，该组合物包括至少一种活性剂和一种非活性基质，所述基质包括壳聚糖及其衍生物，还包括一种亲水性多糖聚合物，该聚合物选自碳水化合物胶类，特别是黄原胶，本发明还涉及所述组合物的制备和使用。